Women Underrepresented Among Grand Rounds Speakers

Share this content:
Women Underrepresented Among Grand Rounds Speakers
Women Underrepresented Among Grand Rounds Speakers

WEDNESDAY, March 15, 2017 (HealthDay News) -- Women seem to be underrepresented among academic grand rounds (GR) speakers, according to a research letter published online March 6 in JAMA Internal Medicine.

Julie R. Boiko, M.D., from the University of California in San Francisco, and colleagues surveyed GR speaker series in clinical specialties and categorized speakers by trainee status, institutional affiliation, and gender. They compared the percentages of female speakers with workforce demographics.

Nine specialties met the inclusion criteria. The researchers found that women presented a median of 28.3 percent of the total sessions, ranging from 20 to 60.3 percent. Trainee-delivered sessions, which made up 2.3 to 24.1 percent of the total sessions, displayed comparable female and male speaker representation. Female representation ranged from 19.6 to 53.3 percent among sessions delivered by faculty or other nontrainees (median, 26.2 percent). When total nontrainee female speaker percentages were normalized to workforce demographic female percentages, the median ratios were 0.56, 0.61, and 0.79 for medical students, residents, and faculty, respectively.

"Women's representation among academic GR speakers falls below the percentage of female medical students (46.7 percent) and residents (46 percent overall) and often falls lower than faculty (36 percent overall)," the authors write. "Representation of women at GR podiums reflects and potentially contributes to limited female retention in academic medicine."

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths